TLDR A patient developed hair loss after hepatitis C treatment with sofosbuvir and ribavirin.
A case report from April 2021 described a rare instance of alopecia areata developing in a patient following treatment with the interferon-free direct-acting antiviral (DAA) therapy combination of sofosbuvir and ribavirin (SOF/RBV) for chronic hepatitis C virus (HCV) infection. Despite the generally low side effects associated with DAA therapies, this case highlighted alopecia areata as a potential, though uncommon, complication.
34 citations,
April 2008 in “Journal of the European Academy of Dermatology and Venereology” Skin problems like itching, dry skin, and hair loss are more common in hepatitis C patients after interferon treatment, but lichen planus is not linked to the infection.
41 citations,
August 2007 in “European Journal of Gastroenterology & Hepatology” A woman's total hair loss from hepatitis C treatment grew back after stopping the medication.
27 citations,
April 2005 in “Journal of Chemotherapy” Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.
9 citations,
May 2005 in “Expert Review of Clinical Immunology” Blocking interferon-gamma might help treat various autoimmune diseases.
January 2024 in “Frontiers in immunology” Histone modification is key in treating chronic inflammatory skin diseases.
3 citations,
May 2023 in “Frontiers in immunology” Faulty inflammasome activation may lead to autoimmune skin diseases and could be a target for new treatments.
January 2025 in “International Journal of Molecular Sciences” Psoriasis involves immune and genetic factors, and understanding these can improve treatments.
3 citations,
June 2023 in “Molecules/Molecules online/Molecules annual” Cepharanthine has many medicinal uses but needs improvement for better effectiveness.
